Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia.

Trial Profile

Phase II Trial of LBH589 (Panobinostat) in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
    • 13 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top